Quadrivalent and bivalent human papillomavirus (HPV) vaccines were licensed for use in 2006 and 2009 respectively. In 2006, the Advisory Committee on Immunization Practices recommended routine vaccination for girls 11 or 12 years of age and catch-up vaccination for girls 13 to 26 years of age. 1 Three years after that recommendation, nearly one-half of girls 13 to 17 years of age in the United States had received Ն1 HPV vaccine dose, and approximately one-fourth had received 3 doses. 2 This is the first analysis to assess factors associated with provider-verified HPV vaccination series initiation and completion among a nationally representative sample of adolescent girls in the United States. The objective of this study was to describe associations between certain sociodemographic characteristics and HPV vaccination series initiation and completion, to inform targeted public health interventions to increase adolescent HPV coverage.
METHODS
The National Immunization Survey (NIS)-Teen is composed of 2 phases, that is, (1) a random-digit-dialed telephone survey of parents/guardians of adolescents 13 to 17 years of age and (2) a survey mailed to all vaccination providers who were identified by the parent and for whom consent was granted. The NIS-Teen represents a stratified, national, probability sample of households in the United States, including all 50 states, the District of Columbia, and selected local areas. It is built on the sampling frame of telephone numbers used by the NIS, which seeks to identify vaccination rates for children 19 All HPV vaccination coverage estimates in this study were determined on the basis of provider records. Only adolescents with adequate provider data (ie, those for whom sufficient vaccination information was obtained from providers for determination of vaccination status) were included in the analysis. Details of the NIS-Teen methods, including procedures for combining vaccination data to produce a synthesized immunization history and weighting procedures, were published previously. 3, 4 HPV vaccine doses were considered valid if the vaccination date was on or after June 8, 2006 , the date of licensure, and if vaccination occurred before or on the date of the interview. Because the third HPV vaccine dose is recommended to be administered 24 weeks after administration of the first dose, series completion was determined among girls who had received Ն1 HPV vaccine dose Ն24 weeks before the interview date.
HPV-related questions from the household interview included parents' knowledge of HPV disease and vaccination and receipt of a provider's vaccination recommendation. Parents who reported that their daughters had not received HPV vaccine were asked, "How likely is it that [your teen] will receive HPV shots in the next 12 months?" Parents who responded "not too likely," "not likely at all," or "unsure" were asked, "What is the main reason [your teen] will not receive HPV shots in the next 12 months?" These questions were open-ended, and responses were coded into categories; multiple responses were allowed. Sociodemographic information included the parent's report of the adolescent's age, race/ethnicity, health insurance type, and health care visits during the past year, household income, mother's education level, age, and marital status, and residential location. With the use of collected data on household income and the number of persons living/staying in the household, income with respect to the federal poverty level (FPL) was determined on the basis of the 2007 and 2008 FPL thresholds defined by the US Census Bureau. Insurance status was categorized as (1) private, (2) Among subjects who completed the household survey, 57.4% had adequate provider-reported vaccination histories. 6 Sociodemographic characteristics of the sample are presented in Table 1 . Overall, 40.5% of girls received Ն1 dose of HPV; the proportion was greater in 2009 (44.1%) than in 2008 (37.0%) ( Table 2 ). Most girls received the first HPV vaccine dose in pediatric offices (75%), and the second most common location was family practice offices (16%) (data not shown). In the multivariate model, vaccination with Ն1 HPV vaccine dose was independently associated with older adolescent age, living in a high-income household, having a mother who never married, having a younger mother, having an 11-to 12-year preventive visit, receiving a provider recommendation for HPV vaccination, insurance status, and facility type where the adolescent received all of her vaccinations ( Table 2) . Several variables were associated with series initiation in the bivariate analysis but were not statistically significant in the multivariate analysis.
Among girls who received Ն1 dose of HPV vaccine, 53.3% received the complete 3-dose series ( Because receipt of a provider recommendation might depend on health care access and use, we performed logistic regression analyses excluding provider recommendation. Independent predictors of HPV vaccination initiation remained the same except for the addition of living in urban versus rural areas (P ϭ .04), having an 11-to 12-year preventive check versus being Ͼ12 years of age at the time of vaccine licensure (P ϭ .01), having private insurance versus being uninsured and VFC-eligible (P ϭ .01), and having parental knowledge of HPV disease (P Ͻ .01) and the vaccine (P ϭ .03). Independent predictors of series completion remained the same except for the addition of living in rural versus urban areas (P ϭ .03) and having SCHIP versus private insurance (P ϭ .05). Bivariate analyses showed statistically significant associations between provider recommendation and race/ ethnicity, having an 11-to 12-year preventive visit, MSA, insurance type, and parental knowledge about HPV and the vaccine (P Ͻ .01 for all).We also assessed associations between selected characteristics and insurance status. Compared with other insurance categories, a larger proportion of VFC-eligible, uninsured girls had no parent-reported health care visits in the past year and received all of their vaccines at public facilities (data not shown). A smaller proportion of VFC-eligible, uninsured girls received Ն1 other adolescent vaccine, compared with girls in other insurance categories.
For girls who had not received HPV vaccine, 32.7% of parents reported that they were very likely to have their daughters vaccinated within the next 12 months, 16.5% were somewhat likely, 13.7% were not too likely, 26.8% were not likely at all, and 10.3% were unsure. Characteristics of parents who intended to have their daughters receive the HPV vaccine within the next 12 months are presented in Fig 1 . Parents who responded "very likely" or "somewhat likely" were considered to have intent to receive the vaccine, whereas parents who responded "not too likely," "not likely at all," or "unsure" were considered to have nonintent to receive the vaccine. A significantly larger proportion of parents who received a provider recommendation intended to have their daughters vaccinated. Other statistically significant results are noted in Fig 1. The most commonly reported reasons given by parents for not intending to have their daughters vaccinated included lack of knowledge about the vaccine (19.4%), vaccine is not needed (18.8%), daughter is not sexually active (18.3%), and did not receive a provider recommendation (13.1%) ( Table 3) . 
DISCUSSION
To our knowledge, this is the first study to examine national data on HPV vaccination initiation and completion among adolescent girls by using provider-verified vaccination records. Approximately 40% of girls received Ն1 HPV vaccine dose and, of those girls, approximately one-half completed the 3-dose vaccination series. Although some factors were associated with both vaccination series initiation and completion, there were differences. Race/ethnicity was not associated with initiation; however, black and Hispanic adolescents were less likely to complete the series, compared with white adolescents. Daughters of younger mothers were more likely to initiate the series, whereas daughters of older mothers were more likely to complete it. Although access to vaccine is provided for uninsured girls through the VFC program, the lack of a medical home might contribute to lower coverage rates among VFC-eligible, uninsured girls and girls who received all of their vaccines at public facilities. The most common reason for nonintent to vaccinate one's daughter against HPV was lack of knowledge about the vaccine. These data provide information that could help identify ways to increase HPV vaccine coverage in the United States.
One of the factors most strongly associated with HPV vaccination initiation was receipt of a provider recommendation. Previous studies showed that provider recommendations influence parental decisions to receive HPV and other vaccinations. [7] [8] [9] [10] Various barriers at the provider level lead to missed opportunities for vaccination, including vaccine costs, insurance coverage, discomfort discussing sexuality, and a preference to vaccinate older adolescents. 11, 12 To address cost and reimbursement barriers, the National Vaccine Advisory Committee recommended improving business practices to ensure vaccine reimbursement, participating in vaccinepurchasing pools, and improving reimbursement through the VFC program. 13, 14 Similar to previous studies, we found that older adolescents were most likely to have initiated HPV vaccination. [15] [16] [17] Although HPV vaccination is recommended for girls at 11 or 12 years of age, pediatricians and family medicine physicians are more likely to recommend HPV vaccination strongly for older adolescents. 12 Strong provider recommendations for HPV vaccination likely would improve vaccine uptake at the recommended age. 8 Limited health care access might hinder receipt of a provider recommendation. In the model without inclusion of provider recommendation, a few additional variables reflecting access to care became significant. Therefore, increasing access to health care, removing provider barriers, and encouraging stronger provider recommendations all could increase vaccine uptake.
Higher coverage rates among older adolescent girls might reflect more opportunities for catch-up vaccination as adolescents grow older. The adolescent platform promotes an 11-to 12-year preventive health check for vaccination and health screening. [18] [19] [20] We found that girls who underwent an 11-to 12-year preventive check were more likely to have initiated vaccination than were those without such a visit. However, there was no difference in coverage rates among girls who underwent an 11-to 12-year preventive check and those who were Ͼ12 years of age at the time of vaccine licensure, which indicates that older adolescents were being vaccinated during subsequent health care encounters. Approximately 50% of girls were Ͼ12 years of age at the time of HPV vaccine licensure, and the 2009 NIS-Teen 1996 birth cohort is the first full cohort that can be assessed for receipt of the HPV vaccine by the 13th birthday. 21 Continued monitoring of subsequent birth cohorts will be needed to assess receipt of the HPV vaccine by the 13th birthday. Efforts to promote an 11-to 12-year preventive check and annual health care visits, as well as use of all visits as opportunities for vaccination, likely will increase HPV vaccination initiation at the recommended age and catch-up vaccination.
There were no differences in HPV vaccination initiation rates according to racial/ethnic group; however, income and insurance status were significantly associated with beginning the vaccine series. The HPV vaccination initiation rate was highest among girls from households with the lowest incomes, the majority of whom were Medicaid-eligible, had SCHIP, or were VFC-eligible and insured; the initiation rate was lowest among VFC-eligible, uninsured girls. The VFC program might be providing better access to HPV vaccination for VFC-eligible, insured girls, compared with girls with other forms of insurance held by non-VFC-eligible girls (ie, private, military, or other insurance). The HPV vaccine is one of the most expensive vaccines, costing $130 per dose in the private sector, and requires a 3-dose series. 22 Because of costs and concerns about reimbursement, some providers might not stock or offer the vaccine, 11, 23 which might contribute to lower vaccination rates among non-VFC-eligible girls. However, HPV vaccination is a covered benefit in the military health system. Few preventive visits, few provider recommendations, and parent and provider attitudes about vaccination might contribute to lower vaccination rates for this group.
Despite VFC eligibility, uninsured girls had the lowest vaccination initiation rate. Lack of insurance is a known risk factor for lack of preventive health care among adolescents 24 and low vaccination rates among young children. 25 For uninsured individuals, health care access is limited to public health facilities or services for which they can self-pay. With insurance, there are more opportunities to access a medical home or usual sources of care, 26, 27 which have been associated with higher vaccination rates. 28 A previous study demonstrated that VFC-eligible children with no medical home were less well vaccinated than VFC-eligible children with a medical home. 29 These observations might explain the higher initiation rate among VFCeligible, insured girls, compared with 
FIGURE 1
Characteristics of parents who intended to have their daughters receive the HPV vaccine within the next 12 months. Parents who responded "very likely" or "somewhat likely" were considered to have intent to receive the vaccine, whereas parents who responded "not too likely," "not likely at all," or "unsure" were considered to have nonintent to receive the vaccine. VFC-eligible, uninsured girls and girls who received all of their vaccines at public facilities. Increasing the proportion of adolescents with health insurance, a primary care physician, and a usual source of care likely would improve health care access and continuity of services. 30 Improved outreach to uninsured adolescents and referrals to VFC providers also might improve vaccination coverage among uninsured girls.
Approximately one-half of the girls who initiated the HPV vaccination series completed it. Reasons for low completion rates might include poor communication of the need for a 3-dose series, failure of patients and parents to return for subsequent doses, fewer health care visits made by adolescents, and lack of a regular source of care. Although VFC-eligible, insured girls were more likely to initiate the HPV vaccination series than were girls with private insurance, fewer completed the series, compared with girls with private insurance. Implementing clinical practice guidelines to use reminder/recall systems likely would increase HPV vaccination series completion rates, 32 particularly for girls who are VFC-eligible and insured or who receive vaccinations in public settings. There were no differences in HPV vaccination initiation rates according to race/ethnicity; however, we found disparities in HPV vaccination completion rates for some racial/ethnic groups. Black and Hispanic girls were less likely than white girls to complete the series. Higher completion rates among black and Hispanic girls might decrease disparities in cervical cancer morbidity and mortality rates, 33 which emphasizes the need for targeted efforts to increase HPV vaccination completion rates; however, additional research is needed for an understanding of the reasons for disparate completion rates for some groups.
Among unvaccinated girls, ϳ40% of parents reported that they were unlikely to have their daughters vaccinated in the next 12 months and 10% were unsure. The lack of knowledge about the HPV vaccine and reports of daughters not being sexually active demonstrate the need for parental education on adolescent risks for HPV infection, stressing the benefits of vaccination and promoting the importance of vaccination before exposure. As in previous studies, few parents (Ͻ1%) reported concerns about increased sexual activity by their daughters after vaccination. 34, 35 This analysis has some limitations. NIS-Teen is a random-digit-dialed survey and is limited to households with landlines. Findings might not be representative of households without landlines and households with only wireless telephones, which would contribute to noncoverage bias. According to data from the 2009 National Health Interview Survey, the number of wireless-only households is increasing; 25.9% of children currently live in wireless-only households. 36 Only 2.4% of children live in households without telephone service. 36 The National Health Interview Survey, a face-to-face household survey that includes landline, nonlandline, and wireless-only households, has been assessed for sociodemographic and health-related variables among adolescents. Benchmark comparisons of these variables for adolescents in the NIS-Teen and the National Health Interview Survey showed no significant evidence of coverage bias with adjustment of sampling weights for noncoverage of nonlandline and wireless-only households in the NISTeen. 37 Nonresponse bias might remain after weighting adjustments. Provider data or vaccination histories might be incomplete. We did not analyze other factors that might influence vaccine coverage, such as state policies. However, state was included in our analyses, to control for multiple unmeasured program factors likely related to the outcome variable. Further analyses will evaluate these program factors.
CONCLUSIONS
Although HPV vaccination coverage is increasing in the United States, it is still below target levels. Provider recommendations are strongly associated with HPV vaccination initiation; recommendations by providers to their adolescent patients and parents likely would improve vaccine uptake. Participating in registries and implementing clinical practice guidelines to use reminder/recall systems to re- Table 2 of the results section, the vaccination coverage estimates reported in the column '3 doses of HPV vaccine among those who initiated series' were not reported among girls who had received $1 HPV vaccine dose $24 weeks before the interview date. They were reported among girls who received $1 HPV vaccine dose any time before the interview date and received the third HPV dose at least 6 months after the first HPV dose. The intention of the authors was to report completion rates among girls who received $1 HPV dose at least 6 months previous to the date of interview to reflect completion rates among girls who had sufficient time to complete the 3 dose HPV vaccination series. Corrected completion rates among girls who received $1 HPV vaccine dose at least 6 months before the interview are reported in the table. We found that HPV vaccination series completion estimates increased after limiting the analysis only to girls who had sufficient time to complete the series before the interview date. On page 833, under the results section, paragraph 3, lines 3-13 read: "In the multivariate analysis, completion of the 3-dose series was independently associated with age of 16 years, black non-Hispanic or Hispanic race/ethnicity, a household income of 133% to ,322% of FPL, having an older mother, parental knowledge about HPV, and facility type where the adolescent received all of her vaccinations." This should have read, "In the multivariate analysis, completion of the 3-dose series was independently associated with ages 14 or 16 years, Hispanic race/ethnicity, a household income of 133% to ,322% of FPL, having an older mother, having SCHIP, parental knowledge about HPV, receipt of a provider recommendation, and facility type where the adolescent received all of her vaccinations." On page 837, under the discussion section, paragraph 6, lines 27-29 read: "Black and Hispanic girls were less likely than white girls to complete the series." This should have read, "Black, Hispanic, and Asian girls were less likely than white girls to complete the series; after controlling for other characteristics, these differences were statistically significant only for Hispanic girls." We regret the error. 
